Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disease areas such as depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease. According to the World Health Organization, WHO, more than 700 million people live with psychiatric and neurological disorders globally. Focus on R&D is the most important pillar in Lundbeck’s ambition to improve treatment for people living with psychiatric and neurological disorders.
Lundbeck employs approximately 5,000 people worldwide. We have employees in 55 countries, and our products are registered in more than 100 countries. We have production facilities in China, Denmark, France and Italy and research centres in Denmark and China. Lundbeck generated revenue of approximately DKK 14.6 billion in 2015. In 2015, 27% of our revenue derived from Europe.